Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Novan, Inc. (Nasdaq: NOVN) announced a presentation by CEO Paula Brown Stafford at the virtual Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:40 AM ET. The event aims to connect management with qualified investors through one-on-one meetings.

A live video webcast of the presentation will be available on Novan's website, along with a replay accessible for 90 days. The company focuses on innovative therapeutic products for skin diseases, notably pursuing FDA approval for berdazimer gel, 10.3% for treating molluscum contagiosum, while also utilizing its NITRICIL™ technology for future treatments.

Presentation with live webcast today, March 14th at 10:40 AM ET

DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual Oppenheimer 33^rd Annual Healthcare Conference today, March 14, 2023 at 10:40 AM ET.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (novan.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Novan

Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. Novan has a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams, promoting products for plaque psoriasis, rosacea and acne. The U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum. The Company also has a pipeline of potential product candidates using its proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com

FAQ

What time will Novan's presentation at the Oppenheimer conference occur?

Novan's presentation at the Oppenheimer 33rd Annual Healthcare Conference will take place on March 14, 2023, at 10:40 AM ET.

Where can I watch the live webcast of Novan's presentation?

The live webcast of Novan's presentation can be found on the Events page of the Investors section of Novan's website.

How long will the replay of Novan's presentation be available?

The replay of Novan's presentation will be accessible for 90 days after the live event.

What is the focus of Novan's therapeutic products?

Novan focuses on developing innovative therapeutic products for skin diseases, including treatments for plaque psoriasis, rosacea, and acne.

What New Drug Application is Novan pursuing with the FDA?

Novan is seeking FDA approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum.